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Initially, indoleamine-2,3-dioxygenase (IDO) has been introduced as a bactericidal effec-
tor mechanism and has been linked to T-cell immunosuppression and tolerance. In recent
years, evidence has been accumulated that IDO also plays an important role during viral
infections including HIV, influenza, and hepatitis B and C. Moreover, novel aspects about
the role of IDO in bacterial infections and sepsis have been revealed. Here, we review
these recent findings highlighting the central role of IDO and tryptophan metabolism in
many major human infections. Moreover, we also shed light on issues concerning human-
specific and mouse-specific host–pathogen interactions that need to be considered when
studying the biology of IDO in the context of infections.
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INTRODUCTION
Indoleamine-2,3-dioxygenase (IDO) is an intracellular, non-
secreted enzyme, which catabolizes the production of kynurenine
(Kyn) derivates from tryptophan (Trp). Anti-proliferative features
of IDO on bacteria, protozoa, and tumor cells have been first
described in 1984 by Pfefferkorn (1) as well as Taylor and Feng
(2). Induction of IDO in cells of the immune system by IFNγ was
introduced for the first time in the late 1980s (3, 4). Today, IDO
is thought to be part of a fast local immune regulatory mecha-
nism called “metabolic immune regulation” to protect the host
from over-reactive immune reactions via induction of systemic
immune tolerance [reviewed elsewhere (5)]. It participates in a
broad spectrum of immune responses during chronic infections,
immune-escape of cancer cells, tissue inflammation, transplanta-
tion, and maternal tolerance toward the fetus and autoimmunity
(6). Interestingly, accumulating evidence also connects enhanced
Trp metabolism to mental disorders based on serotonin starvation.
Exogenous inflammatory stimuli induce the expression of IDO
in antigen-presenting cells (APCs), such as dendritic cells (DC)
(7), macrophages (4), and B-cells. Gene expression of IDO was
found to be regulated by interferon-α (IFNα) and interferon
γ (IFNγ) and also TNFα and prostaglandins (8, 9). As mode
of action for IDO, O2-radical scavenging (2, 10) and later sup-
pression of T-cell responses (11, 12) were discussed. Since many
microbial organisms rely on the essential amino acid Trp, its degra-
dation by IDO-expressing cells of the innate immune system was
favored as the major IDO-mediated mechanism against infec-
tions (13). In infectious disease states, IDO has been shown to
exert pleiotropic effects, even with opposing outcomes. On the
one hand, IDO directly suppresses the replication of certain par-
asites and bacteria (1, 14–16), or at least prevents viral spread
(17–20), on the other hand, it also acts on host cells to suppress
immune reactions thereby promoting infectious diseases (21, 22).
Besides Trp depletion, production of Trp metabolites with bacte-
ricidal activity, like Kyn, were identified in human macrophages
upon infection with diverse bacteria species as another defense
mechanism mediated by IDO (23). IFNγ induced Trp degra-
dation leading to anti-toxoplasmosis activity in infected human
fibroblasts was first described by Pfefferkorn in 1984 (1). Only
a few years later, several studies linked this effect to enhanced
IDO activity against pathogens like Toxoplasma gondii, certain
Chlamydia psittaci strains and Leishmania donovani (14–16). In
these initial studies, IDO-expressing immune cells were described
as macrophages. A contribution of IDO in containment of viral
infections was suggested by in vitro experiments demonstrating
that the inhibition of human cytomegalovirus (CMV) replication
was induced by IFNγ and IFNβ (18). This virostatic effect could be
reverted by addition of exogenous Trp indicating an involvement
of IDO (17, 19, 20). Interestingly, the activity of inducible nitric
oxide synthetase (iNOS) was suggested to be able to substitute for
the IDO-mediated anti-viral mechanism (18, 24). Since then, it
was demonstrated that other viruses, such as herpes simplex virus
type 2 (HSV-2) (17), measles virus (19), and vaccinia virus (20),
are sensible to IDO-induced Trp depletion.
Apparently, pathogens are able to highjack the immunosup-
pressive effects of IDO and make use of them to facilitate their
own life cycle. For instance, uropathogenic Escherichia coli (UPEC)
induce IDO in epithelial cells of the urinary tract and in poly-
morphonuclear leukocytes (21). The dampened immune response
upon IDO induction enables a successful colonization of urinary
epithelium by UPEC. In addition, viruses like human immunode-
ficiency virus 1 (HIV) use the immunosuppressive activity of IDO
to drive HIV infection into the chronic phase (25). In the follow-
ing chapters, we will focus on new insights into the role of IDO
and Kyn derivates in major viral and bacterial infections in mice
and men.
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FIGURE 1 | Schematic summary of immunosuppressive functions of
indoleamine-2,3-dioxygenase (IDO) during HIV infection. Direct induction
of IDO in antigen-presenting cells (APC) by viral Tat protein is established via
an intracellular signaling cascade including kinases (JakI, PI3K) or CTLA-4-B7
interaction on regulatory T (Treg)-cells with B7 co-receptor on the APC, which
leads in consequence to a breakdown of tryptophan (Trp) into kynurenine
(Kyn). Diminished anti-viral immune responses during chronic HIV infection is
caused by an impaired T-cell response, the lack of potent IFNγ secreting DC,
and the induction of immunosuppressive IDO+ APC. pDC, plasmacytoid DC;
mDC, myeloid DC.
ROLE OF IDO IN VIRAL INFECTIONS
ROLE OF IDO IN HIV INFECTION
Infection with HIV causes a severe impairment of T-cell responses
by loss of proliferative capacity of T-cells accompanied by a deple-
tion of functionally competent CD4+ T helper cells and by induc-
tion of regulatory T-cells (Treg) during the chronic phase of HIV
infection (Figure 1). The exact T-cell impairing mechanism is
still not completely understood, but inhibitory molecules on T-
cell function have been investigated intensely [reviewed elsewhere
(26)]. Elevated serum levels of IFNγ (27, 28) and Kyn (29) in HIV
patients pointed toward a participation of IDO in suppression of
T-cell function, yet molecular mechanisms were unknown. Fur-
ther support came from increased IDO mRNA levels measured
in peripheral blood mononuclear cells (PBMCs) of HIV-infected
patients (30). In vitro infection of PBMC led to the secretion of
IFNα and IFNβ by plasmacytoid dendritic cells (pDC) (31). While
both CD4+ and CD8+ T-cells expressed the activation markers
CD69 and CD38, they failed to proliferate and were insensitive to
T-cell receptor stimulation, a status described as division arrest
anergy (32). While CD4+ T-cells were arrested in G1/S phase,
CD8+ T-cells downregulated the costimulatory receptor CD28.
When the enzymatic activity of IDO was inhibited by 1-methyl
tryptophan (1-MT), CD4+ and CD8+ T-cells regained their ability
to proliferate (30, 31). In monocyte-derived DC (moDC), the N-
terminal domain of HIV-1 transactivator regulatory protein (Tat)
induced IFNγ and IDO expression and therefore further led to a
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suppression of T-cell proliferation. Here, 1-MT was also able to
reconstitute T-cell proliferation (33). IDO expression was initially
induced by Tat and followed by the induction of IFNγ leading to a
feed forward loop. Interestingly, IFNγ signaling pathways leading
to IDO expression could be blocked by JAKs and PI3K inhibitors
but Tat-induced IDO expression could not be inhibited, suggest-
ing a novel so far not characterized mechanism of IDO induction
by Tat proteins in HIV infection (33).
In simian immunodeficiency virus (SIV)-infected macaques,
treatment with a combination of antiretroviral therapy (ART) and
1-MT successfully diminished viral loads in plasma and lymph
nodes and restored Trp levels but did not reduce Kyn (34). It
is worth to mention that 1-MT alone was not able to restrain
viremia in this animal model. Probably, IDO was only partially
inhibited since reconstituted Trp levels were accompanied with
elevated Kyn levels in sera of treated animals. Further, a com-
pensatory counterregulatory mechanism for 1-MT was suggested
due to increased IDO and TGFβ production in lymph nodes of
treated animals. Decreased numbers of CD4+ T-cells during the
course of HIV infection are accompanied by a loss of type I IFN
producing cells, like pDC (35, 36). One reason for the low pDC
numbers might be their redistribution to peripheral lymph nodes,
as observed in the acute phase of SIV-infected macaques (36).
Also, numbers of myeloid DC (mDC) are diminished in blood of
HIV patients during primary infection (37). Yet, little is known
about IDO expression in HIV-infected mDC. To investigate, if
HIV alters the function of infected mDC, PBMC-derived DC were
transfected with a HIV containing vector construct as a model sys-
tem (38). This resulted in the induction of IDO in immature and
matured DC, accompanied by increased levels of Kyn. In addi-
tion, elevated levels of TNFα and IFNγ were secreted by these
DC with mature DC secreting the highest amounts. Further, HIV-
transduced mature DC induced only modest T-cell proliferation in
mixed-lymphocyte reactions, which might be due to IDO activity
depleting Trp, a necessary molecule for T-cell function. The addi-
tion of 1-MT restored the immunostimulatory capacity of these
DC, suggesting a central role of IDO in the suppression induced
by HIV-infected DC.
Another mechanism of IDO expression in APCs is mediated
by regulatory T-cells (Treg) (39, 40). In HIV patients, an elevated
enzymatic activity of IDO in APCs was associated with a reduced
anti-viral T-cell response [reviewed elsewhere (41)], while deple-
tion of Treg cells reconstituted anti-HIV immune responses (42).
Similarly, in SIV-infected macaques, the expression of the Treg
markers CTLA-4 and FoxP3 was increased in T-cells of mesenteric
lymph nodes, spleen, and colon, organs with high viral load (43).
Simultaneously, IDO expression in spleen and gut-associated lym-
phoid tissues was suggested to support immunological suppres-
sion in favor of viral replication. Therefore, therapeutic targeting
of Treg in HIV patients thereby reducing IDO expression in APCs
and subsequently immunosuppression seemed promising. How-
ever, when blocking CTLA-4 signaling in SIV-infected macaques,
an unexpected increase in IDO expression and Kyn levels was
observed (44). Moreover, even under conditions of increased T-
cell activation due to loss of the regulatory CTLA-4 signaling, viral
replication was still promoted. Increased IDO levels were sug-
gested to be a consequence of viral replication. In another attempt
to refine ART by combining CTLA-4-blockade and 1-MT treat-
ment, severe side effects causing acute pancreatitis with massive
lymphocyte infiltration into the pancreas and loss of Langerhans
islets were induced (45). Moreover, all tested animals developed
diabetes and hyperglycemic coma while SIV-specific responses
were not observed. These results clearly illustrate that the rever-
sal of immunosuppression by targeting CTLA-4 in chronic viral
infection is not a promising approach.
The influence of IDO expression on viral loads in mice infected
with the retroviral leukemia virus LP-BM5 is controversially dis-
cussed. In an earlier study, higher numbers of pDC in IDO KO
mice correlated with increased levels of type I IFN and reduced
viral load (46). However, in a more recent study using the same
model, IDO had no impact on disease progression (47). Viral loads
of IDO KO mice were comparable to those of wild-type B6 mice
and both IDO KO and WT mice showed decreased responsive-
ness to B-cell and T-cell mitogens. One might postulate that an
important denominator of efficacy targeting IDO might simply
be the time when IDO is induced during the course of the infec-
tion. Clearly, more work is necessary to determine the role of IDO
in murine retroviral infections.
An interesting link between chronic inflammatory diseases and
neurological disorders has been recently made with IDO being
involved. Patients suffering from chronic inflammatory diseases
show often signs of depressive mood behavior (Figure 2). In
patients with chronic HIV infection, the elevated Trp catabolism
maintained by IDO expression is associated with reduced lev-
els of free serum Trp (48, 49). This correlates with a reduction
of serotonin (5-HT) and serotonin transporter (5-HTT) expres-
sion, as well as an accumulation of neurotoxic Trp metabolites
(50). Especially, Kyn and quinolinic acid (QA) can be detected in
cerebrospinal fluids of HIV patients and are linked to the devel-
opment of neuropsychiatric disorders, as part of the Neuro-AIDS
complex of symptoms (50). HIV-1 associated dementia (HAD)
is correlated to IDO and Kyn induced by Tat of HIV-1 clade
B in human primary astrocytes (51) while Tat of HIV-1 clade
C does not induce IDO activity in human primary astrocytes
and is not associated with HAD. Further evidence for the role
of Tat for IDO expression in the brain came from experiments
injecting Tat protein intracerebroventricularly into different mice
strains. Further, when injecting Tat, induction of IDO and sev-
eral other pro-inflammatory cytokines in the brain was associated
with reduced mobility and depressive-like behavior (52), demon-
strating the important role of IDO in the pathophysiology of HIV
infection. Blockade of IDO or upstream events of IDO induction
in chronic infection might be a novel approach to treat chronic
HIV infections.
ROLE OF IDO IN INFLUENZA INFECTION
So far, research of IDO function has focused mainly on murine
influenza infection models. Infection with murine influenza virus
PR8 has been shown to induce IDO expression in mouse lung tis-
sue (53, 54) and lung-associated lymph nodes (54). IDO activity
increased during influenza infection and peak expression cor-
related with increased lymphocyte numbers in the respiratory
tract, albeit the study did not discriminate between T-cell and
B-cell subpopulations (53). In another study, inhibition of IDO
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FIGURE 2 | IDO links chronic viral and bacterial infections to cases of
depression. Underlying mechanisms of the connection between chronic
infection with viruses or bacteria and the onset of mental disorders in men
are unknown. Insufficient levels of serotonin in chronically infected and
depressive patients are thought to be the consequence of constitutively
elevated levels of IDO. Murine models of chronic infections are established to
decipher the involvement of IDO in the development of depressive-like
behavior.
by 1-MT treatment in influenza-infected mice led to increased
numbers of virus-specific memory CD8+ T-cells and functionally
activated effector CD4+ T-cells (55). In a follow-up study, 1-
MT-treatment improved memory T-cell responses correlated with
increased secretion of IFNγ by CD4+ and CD8+ T-cells, accel-
erated Th1 responses, and a broader virus- and epitope-specific
repertoire of CD8+ T-cells (56). Besides, 1-MT treatment led to
improved repair of lung tissue. These results indicate that inhi-
bition of IDO might improve flu vaccine activity, might aid in
heterosubtypic immunity and support a faster recovery. This view
is also supported by data reporting reduced morbidity rates in
IDO KO mice when challenged with RP8 or X31 influenza viruses
(54). Especially, IDO deficiency led to enhanced development of
memory T-cells, which protected mice from lethal virus infection.
Further, it was demonstrated that non-hematopoietic cells from
lung-draining lymph nodes were major IDO producing cells in
response to X31-induced IFNγ secretion. As a feed forward loop,
IFN type I and II induced subsequently IDO activity in hematopoi-
etic cells. As a next step, it will be important to translate these
findings to human influenza infection and design clinical studies
that would allow testing IDO blockade in context of infection
and/or vaccination.
ROLE OF IDO IN HBV AND HCV CHRONIC INFECTION
Indoleamine-2,3-dioxygenase has also been linked to chronic
infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
(57). Despite an appropriate T-cell response during the acute phase
of HCV infection and subsequent viral clearance, T-cell responses
in the chronic phase are weak [summarized by Hiroishi et al. (58)].
A massive amount of HCV-specific CD8 T-cells are recruited to
the liver; however, recognition of viral epitopes is barely present.
Similarly, in chronic HBV infection, cytotoxic T lymphocytes
(CTLs) show only a weak response against the HBV surface anti-
gen (HBsAg). While the molecular mechanisms of the tolerogenic
state in chronic HBV and HCV infection are not completely under-
stood, an increased IDO expression in the liver of patients with
chronic HBV or HCV infection has been observed (57). More-
over, high systemic Kyn/Trp ratios in chronically infected patients
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indicate increased IDO activation. In a recent study including 176
patients suffering from chronic HCV infection and 37 healthy con-
trols, it could be shown that Kyn levels correlated with advanced
liver inflammation and fibrosis (59). Furthermore, monocytes iso-
lated from PBMCs of HCV patients differentiated into IDO+ DC
were more potent in inducing Treg cells when activated with LPS
or IFNγ than those of the control group. Along these lines, in vitro
stimulation of the HCV-infected hepatocellular carcinoma cell line
Huh7 with IFNγ led to an induction of IDO, yet HCV replication
was not altered by IDO activity (57).
Yet another mechanism for induction of IDO expression was
demonstrated in a murine hepatitis model. Treatment with α-
galactosylceramide (α-GalCer), a specific agonist for natural killer
(NK) cells was able to induce IDO (60). It was speculated that
IDO suppresses an overactive immune response triggered by
TNFα-producing NK cells and macrophages infiltrating the liver.
Following the idea of re-establishing immunocompetent CTLs,
wild-type and IDO KO mice were immunized with a combination
of α-GalCer and HBsAg (61). Upon immunization, expression of
the cytokines IL-2 and IL-12b were only increased in IDO KO
mice leading to the induction of HBsAg-specific CTLs. Major
IDO-expressing cells were CD11b+ Ly6G+ myeloid-derived sup-
pressor cells (MDSCs) from spleen, which increased in numbers
after immunization. They directly inhibited the proliferation of
HBsAg-specific CTLs. To assess the role of genes induced by IFNα
and/or IFNγ, Mao et al. co-transfected HepG2 cells with the HBV
core promoter and 37 different expression plasmids for IFNα-
and/or IFNγ-induced genes (62). Only IDO, APOBEC3G, PKR,
and ISG20 reduced HBV DNA levels of more than 60%. IDO was
considered as the major mediator of the IFNγ-induced anti-viral
response, since it mediated Trp depletion followed by suppression
of HBV replication.
ROLE OF IDO IN OTHER CHRONIC VIRAL INFECTIONS
Indoleamine-2,3-dioxygenase might also play a role in several
other viral infections. While infection with Epstein–Barr virus
(EBV) normally causes a self-limited polyclonal lymphoprolifera-
tion, it was shown recently that EBV-transformed B-cells express
elevated levels of IDO causing Trp degradation to Kyn, which – in
turn – suppressed the expression of the activating receptor NK
group 2, member D (NKG2D) receptor on the surface of NK cells
(63). This might be important since NK cells have been suggested
to control the proliferation of EBV-infected B-cells in the acute
phase. In the same report, it was shown that IL18 suppressed the
effect of Kyn on NKG2D expression. It might be speculated that
the suppression of NK cell activation by IDO-expressing EBV-
infected B-cells serves as an escape strategy of the virus. Recently,
it was shown that in vitro generated macrophages expressed IDO
after infection with EBV and displayed T-cell suppressive activi-
ties (64). IDO expression induced by TNFα and IL6 signaling was
mediated by NFκB and the MAP kinase signaling cascade. Both
factors were able to further increase IDO expression, thereby sup-
pressing the proliferative capacity of CD4+ and CD8+ T-cells as
well as dampening their cytolytic activity.
Additional evidence for an important role for IDO in viral
infection was provided in studies of human papilloma viruses
(HPV). Mucosa-tropic HPV are tumorigenic viruses causing
genital cancer, e.g., cervical cancer by inducing epithelial hyper-
plasia (65). Immunotherapy against the tumor is often inef-
ficient because of the existence of a local immunosuppressive
tumor milieu with impaired tumor cell antigen presentation
and resistance of tumor cells against effector mechanisms of T-
cells. The immunosuppressive milieu might be created during
the stage of cervical intraepithelial neoplasia (CIN), since num-
bers of IDO, IFNγ, IL10, and FoxP3 expressing cells are elevated
in CIN compared to normal cervical tissue (66). When HPV16
E7, an envelope- and oncoprotein of HPV was expressed under
the keratin-14 promoter (K14E7) in a skin grafting model, graft
rejection was prevented suggesting that HPV16E7 induced an
immunotolerogenic environment (67). As previously shown, tol-
erance against E7-expressing skin grafts is based on the induction
of IFNγ producing natural killer T (NKT)-cells, which not only
reduce the capacity of CD11c+ DC to cross-present antigens to
CD8 T-cells (68) but also seem to induce IDO expression. In
fact, IDO seems to have a pivotal role in K14E7 graft tolerance,
since IDO inhibition by 1-MT leads to rejection of K14E7 skin
grafts (67). Furthermore, it was observed that skin grafts recruit
higher numbers of DC, which expressed elevated levels of IFNγ
receptor (IFNγR). Especially, dermal Langerin+ (CD207+) DC
expressed IDO and aided in the recruitment of further DC to the
side of transplantation. Clearly, this murine model strongly sug-
gests an important participation of IDO in HPV evasion from host
immunity.
Overall, IDO seems to play an important role in chronic viral
infections mainly by contributing to the establishment of an
immunotolerogenic microenvironment. New strategies to target
IDO itself or upstream mechanisms inducing IDO might help in
the development of therapeutic drugs for patients with chronic
viral infections.
NOVEL ASPECTS OF IDO IN MAJOR BACTERIAL INFECTIONS
ROLE OF IDO IN MYCOBACTERIA INFECTIONS
Tuberculosis (Tb), caused by mycobacteria, is one of the major
human infectious diseases. We and others have linked IDO expres-
sion to this disease (69–72). In Tb patients elevated levels of anti-
inflammatory molecules in the sputum, amongst them IDO have
been detected (70). These immune suppressive mediators, also
including IL10, TGFßRII, and IL1 receptor antagonist (IL1Rn),
have been suggested as biomarkers for Tb. It was assumed that
all these inhibitory molecules dampen Th1 responses in the lung
thereby contributing to immune-escape of the bacteria. While the
direct molecular mechanism of IDO induction in Tb patients is
unresolved, it is clear that IFNγ and TNFα play pivotal roles in
the containment of Mycobacterium tuberculosis (M. tuberculosis)
in humans and in mice (Figure 3). Deficiency of IFNγ or TNFα
expression, or the lack of the respective receptors cause severe
courses of Tb in mice (73–77). From in vitro studies, there is evi-
dence that TNFα might play a role during the acute and chronic
phase of Tb (9, 76). Moreover, treatment of patients with anti-
TNFα antibodies can lead to exacerbation of Tb and the induction
of Tb sepsis (78). In situ studies clearly demonstrated that gran-
uloma formation after M. tuberculosis infection in humans is
associated with high expression of IDO in cells of the center and
the ring wall structure surrounding the center of the granuloma
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FIGURE 3 | Schematic overview of the central role of IDO in immune
responses to bacterial infections. Activation of IDO activity in
bacteria-infected cells induces a potent bactericidal growth restrain to
fight against spreading of the infection. Besides the induction of reactive
oxygen species (ROS) and nitric oxide radicals, activity of IDO aids in Trp
degradation to starve Trp auxotroph bacteria. A further species-specific
bactericidal effect of increased IDO activation is the production of toxic
Kyn metabolites. Recruitment of Treg cells and increasing levels of free
ions might help as negative feedback loop to terminate inflammatory
responses.
(9, 71, 79). Predominant IDO-expressing cells were identified as
CD68+ macrophages and in fewer numbers as CD11c+ S100+ DC.
Both IDO-expressing myeloid cell populations were surrounded
by CD3+ T-cells. The induction of a tolerogenic milieu including
the recruitment of FoxP3+ regulatory T-cells by IDO-expressing
cells together with depletion of Trp most likely aids in the restric-
tion of bacterial spread. IDO seemed to be absent in biopsies of
Mycobacterium leprae (M. leprae) infected skin, suggesting that
IDO is not necessarily involved in all granulomatous diseases.
However, there is still controversy about this, since a recent report
demonstrated expression of IDO in macrophages of leprotic skin
lesions (80).
Further controversy about the role of IDO in Tb comes from a
recent report demonstrating no essential role for IDO in a murine
model of Tb (81). Wild-type as well as IDO KO mice showed
comparable bacterial burden, T-cell responses, and survival rates,
leading to the conclusion that IDO activity is not required for
the control of M. tuberculosis. The authors present no evidence
IDO is indeed expressed in the myeloid cell compartment, like
in human disease, indicating that this mouse model might not
reflect the human situation. In contrast, another report demon-
strates a direct connection between IFNγ and IDO expression
in non-hematopoietic cells, during the chronic phase of murine
M. tuberculosis infection (82). In this model, IDO was expressed
in endothelial and epithelial cells, and IFN receptor deficiency
reduced the levels of expression of IDO in these cells thereby
leading to an impaired long-term control of M. tuberculosis (82).
However, it was also not shown to which extent IDO activity
directly controls M. tuberculosis.
There have been numerous studies during the last 20 years
demonstrating a correlation between Tb and depressive disorders
in patients (Figure 2) (83–86), but many of the underlying mol-
ecular mechanisms remain unclear. To shed some light on the
mechanism, O’Connor et al. utilized a BCG vaccination model
(87). Mice that showed a depressive-like behavior also represented
increased expression of IFNγ, TNFα, and IDO. When studying
IFNγ-R deficient mice, many inflammatory mediators were still
elevated while the expression of TNFα was attenuated and IFNγ
and IDO were absent in lung or brain tissue. Furthermore, the lack
of IDO activity in IFNγ-R deficient mice resulted in diminished
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plasma ratios of Kyn/Trp. The authors assumed a synergistic effect
of IDO and TNFα on microglia of BCG-treated mice since pre-
treatment of mice with a TNFα antagonist was able to attenuate
TNFα expression and to abrogate depressive-like behavior. Fur-
ther studies need to clarify whether TNFα is actually upstream of
IDO and blockade of TNFα can reduce IDO expression and func-
tion. Downstream of IDO, BCG also increased the expression of
3-hydroxyanthranilic acid oxygenase (3-HAO), which participates
in the generation of the neurotoxic Kyn metabolite QA (88). Appli-
cation of 1-MT also prevented the development of depressive-like
behavior after BCG inoculation in mice, suggesting that elevated
IDO, like TNFα, contributes to the onset of depressive disorders
during chronic inflammation caused by mycobacteria.
ROLE OF IDO IN CHLAMYDIA INFECTIONS
Indoleamine-2,3-dioxygenase was also shown to be important
in the defense against the ubiquitous intracellular bacterium
Chlamydia pneumoniae (C. pneumoniae),which causes respiratory
tract infections and is associated with chronic diseases like asthma.
In general, the life cycle of Chlamydia species can be divided into
two phases: (1) a stage of infectious but metabolically inactive form
directly after uptake of the bacteria into the host cell, and (2) a stage
of differentiation and multiplication enabled by an active metabo-
lism. It can be assumed that immune responses of host cells might
differ according to the life cycle of Chlamydia. Njau et al. recently
demonstrated that C. pneumoniae infection of human moDC-
induced IDO expression in a TNFα-dependent manner and IDO
was sufficient to restrain bacterial growth (89). TNFα-dependent
bactericidal effects on C. pneumoniae were abrogated after sup-
plementation of Trp. Since C. pneumoniae is Trp auxotroph, the
authors concluded from these experiments that Trp depletion is
detrimental for C. pneumonia growth. In C. pneumoniae-infected
THP-1 cells, an induction of IDO, TNFα, and neopterin could
be demonstrated (90). However, IDO activation in combination
with increased Trp degradation as well as IFNγ treatment had no
effect on numbers or growth of C. pneumoniae in THP-1 cells.
This observation was explained by the ability of C. pneumoniae to
survive even under conditions of low Trp concentrations, going
into a latent state without proliferation and differentiation. An
interesting aspect of this study was the comparison of chlamydia
infection in THP-1 cells and human endothelial cells. While IDO
was already induced in monocytic cells upon infection and was
further elevated by IFNγ, infected and non-infected endothelial
cells required IFNγ stimulation to induce IDO expression. Only
after IFNγ-treatment, suppression of proliferation of C. pneumo-
niae in endothelial cells was observed. The authors also argued
that the differences between the two cell types might also reflect
different stages of the C. pneumoniae infectious cycle. The bacteria
might use immune competent monocytes as transportation ves-
sels for systemic dissemination, while endothelial cells might serve
as habitats for differentiation and proliferation, especially under
iron rich conditions.
An interesting link between IDO and iron metabolism has been
suggested by Krausse-Opatz and colleagues (91). In a hepatic cell
line infected with Chlamydia trachomatis (C. trachomatis), they
could demonstrate that increased intracellular levels of ferrous
iron FeSO4 attenuated IFNγ-induced IDO expression leading to
increased infectious yields. Similarly, the human monocytic cell
line THP-1 has been shown to be sensitive to low iron concen-
trations, which showed an inhibitory effect on IFNγ signaling
resulting in decreased Trp metabolism (92). This observation led
to the hypothesis that immune cells retain iron during inflamma-
tory diseases to enable efficient IFNγ driven immune responses.
On the other hand, reduction of iron levels by deferoxamine did
not reconstitute IDO activity, but still suppressed bacterial growth
(90, 91). Leonhardt et al. addressed whether IDO-mediated Trp
depletion is responsible for suppression of bacterial growth of C.
trachomatis (93). They used HeLa cells, an immortalized cervi-
cal carcinoma cell line, as the model for infection. Interestingly,
the lack of available Trp in IDO competent HeLa cells led to an
impairment of intracellular bacteria trafficking toward the perin-
uclear microtubule-organizing center after entrance into the host
cell. Bacteria displayed low transcriptional activity, lost their infec-
tivity, and remained scattered in the periphery of the HeLa cells.
Since most of the recent work concerning the influence of iron
ions has been performed in cell line models, it remains an unan-
swered question, whether these observations will hold true, once
primary human cells are used for analysis.
ROLE OF IDO IN COMMUNITY-ACQUIRED PNEUMONIA AND SEPSIS
Another area of great interest during the last years has been the
function of IDO during community-acquired pneumonia (CAP)
and sepsis. Already in 2005, increased Kyn levels in trauma patients
with bacteremic sepsis, respiratory distress syndrome, or multi
organ dysfunction/failure pointed toward a role for IDO in sep-
sis (94). In a larger cohort-study, Suzuki and colleagues investi-
gated 129 patients and 64 healthy controls and revealed increased
Kyn/Trp ratios as prognostic marker for severity and morbidity of
CAP caused by multiple pathogens (95). Along these lines, several
independent studies reported increased IDO activity as predic-
tor of severity and mortality of sepsis (96–98). Elevated Kyn/Trp
ratios as indicator of IDO activity in plasma of sepsis patients also
correlated with elevated levels of IFNγ and IL10, which were also
shown to further trigger IDO activity (96). Furthermore, these
patients show reduced CD4+ and CD8+ T-cell counts similarly
pointing to an overall impairment of immune functions during
sepsis. There was also an inverse correlation between elevated
Kyn/Trp ratios and NO-dependent microvascular reactivity as a
surrogate marker for endothelial cell function, as mean arterial or
diastolic blood pressure were reduced. Direct measurement of IDO
activity in patients with sepsis or septic shock showed a gradual
increase of IDO activity with severity of sepsis, which was directly
associated with mortality (97). The major sources of IDO were cir-
culating CD14+ monocytes, which were increased both absolutely
and relatively compared to other white blood cells during sepsis.
Interestingly,ex vivo stimulation of monocytes from septic patients
with IFNγ led to the induction of functional IDO and was found
to be independent of NFκB signaling while other TLR agonists like
LPS-induced IDO expression in an NFκB dependent fashion (97).
Along these lines, hints for a novel IDO-inducing mechanism
were found in a murine mouse model in which the induction
of IDO in context of sepsis was investigated. Mice which are defi-
cient in serine/threonine kinase, general control non-derepressible
2 (GCN2) gene were protected from endotoxic shock (99). This
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was associated with a rapid induction of IDO in spleen and an
increased Kyn/Trp ratio in serum suggesting that elevated IDO
levels in sepsis might actually be beneficial. However, this does
not seem to be necessarily the case since IDO deficient mice
also are resistant against LPS-induced septic shock (100). Simi-
larly, inhibition of IDO activity by 1-MT during endotoxin shock
in vivo was associated with increased survival (100). Whether these
results can be translated to humans has to be proven. In this con-
text, it is interesting to mention that application of GMCSF in
sepsis patients was associated with suppression of IDO activity
and reduction of free Kyn metabolites (101). Experimental proof
for concomitant improvement of antibacterial defense has to be
further investigated.
Overall, IDO also seems to play a role during clinically relevant
infections such as CAP and sepsis. Whether IDO might become a
therapeutic target in these patients is still to be investigated.
ROLE OF IDO IN LISTERIA INFECTIONS
During the last years, we have defined the role of IDO in human lis-
teriosis (8, 9, 23, 69, 79, 93, 102). Listeriosis is a foodborne disease
caused by oral infection with Listeria monocytogenes (L. monocy-
togenes). Newborn infants are prone to infections due to incom-
pletely developed cell-mediated immunity. Early on, we could
demonstrate that induction of IDO in myeloid cells after L. mono-
cytogenes infection is TNFα dependent (9). Chronic listeriosis is
characterized by the development of granulomatous structures
encapsulating bacteria-infected cells to restrain bacterial spread-
ing. IDO-expressing CD68+ macrophages and S100+CD11c+
DC, but not T- or B-cells, are part of the ring wall structure in
these granuloma. When analyzing the effect of L. monocytogenes
infection on DC function, we observed an inhibitory effect of
these DC on T-cell proliferation and cytokine expression. Fur-
thermore, we demonstrated that the inhibitory effect is mediated
by IDO and the TNFα-dependent production of suppressive mol-
ecules like IL10, COX2, and soluble CD25 (69). Initial experi-
ments addressing the IDO-mediated inhibitory effects on T-cells
suggested that IDO-mediated Trp depletion and also the produc-
tion of toxic metabolites were responsible for the observed loss
of T-cell proliferation and cytokine production (69, 102). More
recently, we were interested to understand whether bactericidal
effects exerted by IDO-expressing human myeloid cells is mainly
due to Trp depletion or toxic metabolites (23). Earlier work in
mice and in human cells, as well as in other bacterial infections
showed conflicting results concerning the role of these two bac-
tericidal mechanisms. Using primary human macrophages and
DCs, we could show unequivocally that it is not Trp depletion but
rather Kyn metabolites that exert the bactericidal effect against L.
monocytogenes. Especially, 3-hydroxy-kynurenine (3HK) was the
most potent Kyn metabolite. Moreover, this bactericidal effect was
also seen for other Listeria strains including Listeria innocua. It is
important to note that these findings only reflect IDO biology in
humans, since we could also clearly show that IDO is not induced
in murine DC and macrophages after infection with L. monocy-
togenes. In contrast, murine L. monocytogenes infected myeloid
cells produced iNOS instead of IDO. One explanation of the
observed species-specific differences might be a differential expres-
sion of the iNOS cofactor tetrahydrobiopterin, which is expressed
by murine primary macrophages as well as murine macrophage
cell lines after activation with IFNγ and LPS (103, 104). In fact,
murine IFNγ stimulated macrophages showed a strong correla-
tion between tetrahydrobiopterin and NO levels (104). In contrast,
tetrahydrobiopterin was shown to be expressed only at very low
levels in human monocytes and macrophages (104, 105). A fur-
ther explanation for this divergent usage of IDO and NO between
mice and men came from a study, which revealed an inhibitory
effect of NO on IDO in primary IFNγ-activated human periph-
eral mononuclear cells and macrophages (106). An interaction of
NO with the heme iron at the active site of IDO preventing the
conversion of ferric iron, necessary for IDO activity, has been pro-
posed to be responsible for the inhibitory effect of NO on IDO
(107). IDO inhibition might also rely on rapid removal of oxygen
radicals by NO, which are required for IDO activity (108, 109).
Such a clear-cut species-specific difference in usage of effector
molecules as well as diverging susceptibilities against pathogens
between mice and men are not too surprising since both species
have evolved in different habitats, being exposed to completely dif-
ferent sets of pathogens. These observations further support the
notion that one needs to be very careful when studying murine
IDO in infection models and translating gained knowledge back
to human diseases such as listeriosis or Tb.
SUMMARY/CONCLUDING REMARKS
Recent findings have clearly revealed that elevated IDO expres-
sion is a hallmark of major human viral infections including
HIV, HBV, HCV, or influenza, and also major bacterial infections
such as Tb, CAP, listeriosis, or sepsis. Besides Trp depletion, pro-
duction of ROS or the modulation of Trp metabolism by iron
ions via IFNγ have to be considered as part of a complex net-
work participating in the fight against pathogens. An elevated
Kyn/Trp ratio as a surrogate for IDO activity seems to be a hall-
mark for these infectious diseases and as demonstrated for sepsis
patients seem to correlate with the severity of disease. So far,
the major role of elevated IDO activity has not been definitely
established. Both anti-pathogen and immunosuppressive mecha-
nisms have been suggested. In this scenario, IDO activity might
be a dual sword, fighting the pathogen directly by a metabolic
mechanism, while keeping an overwhelming immune response in
check. Whether this delicate balance between pathogen defense
and host protection from lateral damage induced by IDO could
be utilized therapeutically to further optimize the host response
during infection remains to be seen. So far, it is not clear whether
a further increase of IDO activity would indeed be beneficial. It
might enhance the anti-pathogenic effect, but further elevating
immunosuppression might actually be detrimental to the host
during infection.
In fact, data from septic patients as well as studies from murine
sepsis models utilizing LPS to induce septic shock would actu-
ally speak against enhancing IDO activity. On the contrary, in
these models, depletion of IDO function is actually beneficial
to the host. As exemplified above, interpreting the role of IDO
for human Tb might be very misleading when based on murine
models that do not reflect human disease properly. Moreover,
we have clearly established that IDO is differentially regulated
in murine and human myeloid cells in response to infection
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with L. monocytogenes and probably also other viral and bac-
terial infections. Particularly when studying the myeloid com-
partment, we strongly recommend to study regulation and func-
tion of IDO first in humans. If IDO is involved, the findings
should be translated into the murine model. However, if there
is no evidence for IDO regulation in the same cellular compart-
ment in the murine infection model, then it will be necessary
to either use other more informative animal models or to apply
other approaches in the human setting. For future research, it
will be extremely important to develop structured datasets that
can be quickly interrogated to understand whether gene func-
tion observed in human disease is also apparent in major animal
models, particularly the murine system. So far, such data are
missing.
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